Archives
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2018-07
-
Future analysis could consider using fixed effects also with
2019-09-04
Future analysis could consider using fixed effects also with the level set field, , in order to investigate which covariates explain the classification, a feature of the proposed model that we have not yet investigated. Further, multi-type point patterns may also be analyzed with the proposed model
-
maleate and To better understand the mechanism of
2019-09-04
To better understand the mechanism of splicing in CLCN1, we began by constructing a minigene spanning exons 5–7 of CLCN1, resulting in the synthetic CLCN1 (5–7) minigene. We also established a new assay using real-time reverse transcription (RT)-PCR, which can distinguish between splicing variants b
-
Acknowledgments The authors thank Dr
2019-09-04
Acknowledgments The authors thank Dr. Vladimir Poltoratsky and Zhihui Xiao for their help with the in vitro FRET assay. Support for this research was provided by Saint John’s University. Introduction We predicted the existence of endothelium-derived contractile factors (EDCFs) in 1982 [1]. In 1
-
Digoxigenin-11-dUTP pathway Real time PCR as described previ
2019-09-03
Real-time PCR, as described previously with minor modifications, was used to detect DNA . The PCR mixture (Qiagen) was as follows: 5mM MgCl2, 2.5μl of 10x PCR Buffer, 0.125μl of HotStarTaq DNA Polymerase, 0.25mM of each dNTP, 0.4μM of each primer and 0.1μM of FAMlabelled probe (‘5-aacaattggagggcaag
-
br Conclusions Present work comprehensively characterizes
2019-09-03
Conclusions Present work comprehensively characterizes the inhibitory activity of Yersinia enterocolitica against cysteine proteases. All tested strains, regardless of their bioserotype, genotype and the presence of virulence markers, synthesized the high-molecular-weight inhibitors of papain and
-
The most important finding in the
2019-09-03
The most important finding in the present study is that the EKR1/2-Egr-1 signaling pathway might be involve in the mechanisms underlying CysLT2 receptor-mediated IL-8 production. The signaling profile can be described by the following sequential processes: the agonists (LTC4 and LTD4) activates CysL
-
Here we describe a novel series of arylazoderivatives
2019-09-03
Here, we describe a novel series of arylazoderivatives developed from CAN508, one of the first known selective CDK9 inhibitors. We focused on modification of both ends of parental molecule, CAN508, in order to improve cytotoxicity and CDK activity. We therefore analyzed how changes in molecules will
-
To respond to the need for QNAT commercial assays
2019-09-03
To respond to the need for QNAT, commercial assays have been developed on automated systems. The first reagents for CMV and EBV VLs in whole blood were Abbott RealTime kits on the m2000 SP/RT system (Abbott Molecular Inc, Des plaines, USA) (M2000) [4,5] and Artus QS-RGQ kits on the QIAsymphony RGQ
-
Our study has several limitations As this study
2019-09-03
Our study has several limitations. As this study was performed at a single institution, it had a limited sample size and was not powered to detect specific differences in assay performance by organ group or waitlist status. In the two CMV seropositive subjects with potential passive antibodies, the
-
When a hour delay period was implemented for the
2019-09-03
When a 6-hour delay alpha msh was implemented for the WRAM, neither of the E2-treated groups (E2-only and E2 + Levo) differed in WMC errors between the postdelay trials and the baseline trials. This suggests that exogenous E2 treatment protected from a delay-induced impairment in performance on wor
-
br Conclusions We can conclude that Arg is
2019-09-03
Conclusions We can conclude that Arg293 is important but not indispensable for MeGlcA recognition by EcXyn30A since the R293A variant still retains activity and preference for MeGlcA-substituted substrates. The substrate specificity of GH30_8 glucuronoxylanases is most probably determined by an o
-
More recent studies have correlated sPLA
2019-09-03
More recent studies have correlated sPLA2-V with alternative macrophage activation (M2) in human and murine macrophages [149,150]. sPLA2-V expression was induced during both human and mouse interleukin-4–mediated activation of macrophages in vitro, and its absence impaired macrophage activation in v
-
Moreover considering that several polyphenols and flavonoids
2019-09-03
Moreover, considering that CK 666 clinical several polyphenols and flavonoids (i.e. chalcones, flavanones, resveratrol derivatives, ellagic acid) are reported to inhibit tyrosinase and elastase (Pillaiyar et al., 2017; Xing et al., 2016; Wittenauer et al., 2015), the relations between enzyme inhibi
-
Recently cross talk between DDR and
2019-09-03
Recently, cross-talk between DDR2 and the insulin receptor and between Notch1 and DDR1 was proposed. Stimulation of cells with collagen I and insulin promotes Tyr740 as well as total tyrosine phosphorylation of DDR2 receptor to a greater extent than the phosphorylation stimulated by collagen I alone
-
The loss of secondary mutation T
2019-09-03
The loss of secondary mutation T790M mutation after AR and SCLC transformation was also reported for Rociletinib. Piotrowska et al. using the MGH NGS platform recently reported in 13 biopsies among 12 EGFR T790M+ patients progressing after treatment with Rociletinib the loss of EGFR T790M mutation i
14939 records 980/996 page Previous Next First page 上5页 976977978979980 下5页 Last page